Search

Displaying results 621 - 630 of 1101 in total
  1. Drug

    Avalglucosidase alfa

    go.drugbank.com/drugs/DB16099
    ApprovedInvestigational

    Avalglucosidase alfa, or NeoGAA, is a drug for enzyme replacement therapy specifically designed for Pompe disease, a rare inherited neuromuscular disorder caused by the deficiency of the alpha-glucosidase (GAA) enzyme. GAA is an essentia...

  2. Drug

    Patiromer

    go.drugbank.com/drugs/DB09263
    ApprovedInvestigational

    Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015.

  3. Drug

    Cipepofol

    go.drugbank.com/drugs/DB16295
    ApprovedInvestigational

    [L63931] It is indicated only for induction of general anesthesia, with another agent used up for maintenance. … [L63809,L63931] At the time the labeling was issued in May 2026, both the initial U.S. approval date and the controlled substance schedule remained pending review by the Drug Enforcement Administration

  4. Drug

    Hexaminolevulinate

    go.drugbank.com/drugs/DB06261
    ApprovedInvestigational

    On May 28, 2010, the U.S.

  5. Drug

    Trastuzumab deruxtecan

    go.drugbank.com/drugs/DB14962
    ApprovedInvestigational

    Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavabl...

  6. Drug

    Elranatamab

    go.drugbank.com/drugs/DB15395
    ApprovedInvestigational

    Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb, each...

  7. Drug

    Melphalan

    go.drugbank.com/drugs/DB01042
    ApprovedInvestigational

    Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of mul...

  8. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    [A275423,L56053] Pegzilarginase-nbln received accelerated approval from the U.S.

  9. Drug

    Anagrelide

    go.drugbank.com/drugs/DB00261
    ApprovedInvestigational

    [L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g.

  10. Drug

    Cobimetinib

    go.drugbank.com/drugs/DB05239
    ApprovedInvestigational

    It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.